No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US Stock MarketDetailed Quotes
DOMA Doma Holdings
- 6.0500
- -0.0400-0.66%
Close Jul 19 16:00 ET
85.60MMarket Cap-792P/E (TTM)
6.1300High6.0500Low6.44KVolume6.0500Open6.0900Pre Close39.22KTurnover0.06%Turnover RatioLossP/E (Static)14.15MShares9.400052wk High-2.05P/B61.72MFloat Cap3.860052wk Low--Dividend TTM10.20MShs Float265.2500Historical High--Div YieldTTM1.31%Amplitude3.8600Historical Low6.0950Avg Price1Lot Size
Pre-Market
- 5D
- Daily
- Weekly
- Monthly
- 1Q
- 1Y
Trade Overview
Unit: --
Capital Trend
IntradayDayWeekMonth
No Data
News
Express News | NYSE Order Imbalance 193790.0 Shares on Sell Side
Doma Holdings Cut to Market Perform From Market Outperform by JMP Securities
Doma Holdings Cut to Market Perform From Market Outperform by JMP Securities
JMP Securities Maintains Doma Holdings(DOMA.US) With Hold Rating
JMP Securities analyst Matthew Carletti maintains $Doma Holdings(DOMA.US)$ with a hold rating.According to TipRanks data, the analyst has a success rate of 58.5% and a total average return of 10.6% ov
JMP Securities Downgrades Doma Holdings(DOMA.US) to Hold Rating
JMP Securities analyst Matthew Carletti downgrades $Doma Holdings(DOMA.US)$ to a hold rating.According to TipRanks data, the analyst has a success rate of 58.5% and a total average return of 10.6% ove
JMP Securities Downgrades Doma Holdings (DOMA) to a Hold
10-Q: Quarterly report
Comments
Investors' belief in Doma Holdings' weak revenue growth outlook may be causing its low P/S ratio. Without significant changes, it's hard to see the stock price rising drastically.
Improved Revenues Required Before Doma Holdings Inc. (NYSE:DOMA) Stock's 26% Jump Looks Justified 1
Investors may anticipate Doma Holdings' continued poor revenue performance, which might justify its low P/S ratio. The company's inferior revenue forecasts in comparison to the industry may continue to constrain its share price.
$Lixte Biotechnology(LIXT.US$ 700k float / 60% institutional /67% CTB
$Grove Collaborative(GROV.US$ 16m float / 74% institutional/ 30% CTB
$Acorda Therapeutics(ACOR.US$ 1.2m float/ 18% institutional/ 37% CTB
$Verastem(VSTM.US$ 16m float / 40% institutional/ 18% CTB
$Cibus Inc(CBUS.US$ 16m float / 12% institutional
$Bone Biologics(BBLG.US$ 27m float / 17% institutional/ 127% CTB
$Greenlane(GNLN.US$ 1.5m float/ 17% institutional/ 35% CTB
$VistaGen Therapeutics(VTGN.US$ 7.2m floa...
$Grove Collaborative(GROV.US$ 16m float / 74% institutional/ 30% CTB
$Acorda Therapeutics(ACOR.US$ 1.2m float/ 18% institutional/ 37% CTB
$Verastem(VSTM.US$ 16m float / 40% institutional/ 18% CTB
$Cibus Inc(CBUS.US$ 16m float / 12% institutional
$Bone Biologics(BBLG.US$ 27m float / 17% institutional/ 127% CTB
$Greenlane(GNLN.US$ 1.5m float/ 17% institutional/ 35% CTB
$VistaGen Therapeutics(VTGN.US$ 7.2m floa...
41
22
$Doma Holdings(DOMA.US$ looking into trying to get in at .65 earnings release after will probably drop then go back up
Read more
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
%Chg